With strong results in hand from the phase I stage of its phase I/II study testing a would-be COVID-19 subunit vaccine, Novavax Inc.’s president of R&D, Gregory Glenn, said “it’s possible we could go down in the dose” as work proceeds and get similar efficacy. Read More
Citing the limited supplies and the pricing of the COVID-19 therapy, nearly three dozen U.S. states and territories are clamoring for the federal government to march in on Gilead Sciences Inc.’s patents for remdesivir. And if the feds won’t, then states should be given that authority, according to a letter sent Tuesday to the Department of Health and Human Services, the NIH and the FDA. Read More
HONG KONG – Venture capital investment into most sectors in China has generally plunged throughout the COVID-19 pandemic but biotechnology has been a noticeable exception. Read More
Matterhorn Bioscience AG has launched to develop T-cell receptor therapies based on the power of MR1T cells that have been found to find and kill a range of tumors in various tissue organs. Read More
PERTH, Australia – Patients with relapsed or refractory acute myeloid leukemia (r/r AML) who have received three or more lines of therapy are often too sick to get much-needed bone marrow transplants and often run out of options. Melbourne-based Race Oncology Ltd. hopes to change those outcomes with a new take on an old drug that slipped through the cracks in the 1980s. Read More
HONG KONG – The recent approval of all-oral hepatitis C virus (HCV) drug RDV/DNV, a combination of Asclevir (ravidasvir) and Ganovo (danoprevir), helped boost shares of Ascletis Pharma Inc. (HK:1672), which ended July with a 10% jump to HK$3.36 (US43 cents), as the Hangzhou, China-based company continues to push its pipeline of treatments forward and improve its outlook. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Axcella, Biontech, Clovis, Cytodyn, Elios, Emmaus, Fosun, Hepion, KBP, Modag, Novavax, Palatin, Pfizer. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adicet, Aerpio, Alvotech, Celularity, Cohbar, Evotec, Genfit, IMV, Recursion, Regeneron, Scholar Rock, Secarna, Specifica, SRI, Teva, Therapeutics Solutions, Torii, VBI, Verrica, Viacyte, Vyripharm. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Axsome, Diurnal, Pharmacyte, Revive. Read More
